Meeting
2022 ASCO Annual Meeting
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
Authors
Michael W. Bishop
St. Jude Children's Research Hospital, Memphis, TN
Michael W. Bishop , Yimei Li , Rachel Christine Brennan , Sara Michele Federico , Elizabeth Stewart , Mark Edward Hatley , Sara Helmig , John Thomas Lucas , Christopher L Tinkle , Andrew M. Davidoff , Mary B McCarville , Karen H. Albritton , Daniel J. Indelicato , Alberto S. Pappo , Matthew J. Krasin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01871766
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 10031)
DOI
10.1200/JCO.2022.40.16_suppl.10031
Abstract #
10031
Poster Bd #
246
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A pilot trial of irinotecan, temozolomide and bevacizumab (ITB) for treatment of newly diagnosed patients with desmoplastic small round cell tumor (DSRCT).
First Author: Heather D. Magnan
Poster
2016 ASCO Annual Meeting
BERNIE: Open-label, randomized, phase II study of bevacizumab plus chemotherapy in pediatric metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).
First Author: Julia C. Chisholm
Poster
2012 ASCO Annual Meeting
The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma (mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS).
First Author: Julia C. Chisholm
Poster
2022 ASCO Annual Meeting
Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.
First Author: Danielle Klingberg